Bone drug works for breast cancer survivors
NEW YORK (Reuters Health) - Risedronate, better known by the brand name Actonel, is effective for maintaining or improving the bone strength of women who have had chemotherapy for breast cancer, researchers report.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=UEPXcN" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=UEPXcN)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=ZTAOfI" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=ZTAOfI) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=XM3eei" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=XM3eei) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=xJHBji" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=xJHBji)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/314883947" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/314883947/idUSTON87407520080618